Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — HARVARD BIOSCIENCE INC

Accession: 0001171843-26-007308

Filed: 2026-11-10

Period: 2026-11-10

CIK: 0001123494

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — f8k_110726.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (exh_991.htm)

GRAPHIC (logo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: f8k_110726.htm · Sequence: 1

false

0001123494

0001123494

2026-11-10

2026-11-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33957

04-3306140

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

84 October Hill Road

Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

HBIO

The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined

in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2

of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected

not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section

13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2026, Harvard Bioscience, Inc. (the “Company”)

issued a press release announcing financial results for the three and nine months ended September 30, 2026, and the details of a related

conference call to be held at 8:00 AM ET on November 10, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein

by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached

hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange

Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under

the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release issued by Harvard Bioscience, Inc. on November 10, 2026

104

Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly

caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC.

Date: November 10, 2026

By:

/s/ Mark Frost

Mark Frost

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exh_991.htm · Sequence: 2

Exhibit 99.1

Harvard Bioscience Announces Third Quarter 2026 Financial Results

· Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million

· Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth

HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience,

Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter

ended September 30, 2026.

“We delivered our second consecutive quarter of strong year over

year growth with an 8% topline increase in the third quarter,” said John Duke, President and Chief Executive Officer. “We

saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and

fluidics products. Our revamped sales and marketing teams are delivering encouraging results, and Project Viking remains on track for

completion by the end of the first quarter in 2027. Looking ahead, our sales momentum, continued New Product Innovation (NPI) adoption,

and progress on key initiatives give us confidence in the trajectory of the business.”

Third Quarter 2026 Results

For the third quarter of 2026, the Company reported revenues of $22.2 million

compared to $20.6 million in the third quarter of 2025. Revenue for the third quarter of 2026 included an unfavorable impact from foreign

currency exchange rates of less than 1%, using a constant currency basis. Gross profit for the third quarter of 2026 was $12.3 million

compared to $12.0 million in the third quarter of 2025. Gross margin for the third quarter of 2026 was 55.4%, compared to 58.4% in the

third quarter of 2025.

Adjusted gross profit and adjusted gross margin for the third

quarter of 2026 were $12.7 million and 57.1%, respectively, compared with $12.2 million and 59.2% in the same period of the prior year.

Net loss for the third quarter of 2026 was $(2.6) million, compared

to a net loss of $(1.2) million in the third quarter of 2025. Adjusted EBITDA for the third quarter of 2026 was $1.8 million compared

to $2.0 million in the third quarter of the prior year. Cash (used in) provided by operations was $(0.2) million during the three months

ended September 30, 2026 compared to $1.0 million in the same period of the prior year.

Nine Months Ended September 30, 2026 Results

For the nine months ended September 30, 2026, the Company reported

revenues of $65.7 million, compared to $62.8 million in the same period of the prior year. Revenue for the nine months ended September

30, 2026, included a favorable impact from foreign currency exchange rates of approximately 1.2%, using a constant currency basis. Gross

profit was $37.2 million for the first nine months of 2026 compared to $35.7 million in the same period of the prior year. Gross margin

for the nine months ended September 30, 2026, was 56.6% compared with 56.9% in the same period of the prior year.

Adjusted gross profit and adjusted gross margin for the nine

months ended September 30, 2026, were $38.0 million and 57.9%, respectively, compared with $36.3 million and 57.7% in the same period

of the prior year.

Net loss for the nine months ended September 30, 2026, was $(9.0)

million compared to a net loss of $(53.9) million in the same period of the prior year, primarily due to goodwill impairment in the first

quarter of 2025 of $48.0 million. Adjusted EBITDA for the nine months ended September 30, 2026, was $4.2 million, compared to adjusted

EBITDA of $4.3 million for the same period of the prior year. Cash (used in) provided by operations was $(0.6) million during the nine

months ended September 30, 2026 compared to $6.8 million in the same period of the prior year.

This press release includes certain financial information presented

on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, see

“Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Fourth Quarter 2026 Guidance

The Company’s fourth quarter outlook at the midpoint of

the guidance ranges reflects expected year-over-year revenue growth driven by ongoing demand across Cellular & Molecular Technology

(CMT) and NPI platforms, sequential gross margin expansion, and improving year-over-year profitability on an adjusted EBITDA basis. The

Company expects:

· Revenue between $23.7 million and $25.5 million

· Adjusted gross margin between 59% and 61%

· Adjusted EBITDA between $3.8 million and $4.2 million

Full Year 2026 Guidance

The Company is reaffirming its full-year 2026 revenue and gross

margin guidance while updating its full-year adjusted EBITDA target to account for higher-than-expected sales of certain lower-margin

CMT products and higher revenue contribution from distribution channels and China. The Company now expects:

· Revenue growth between 3% and 5%

· Adjusted gross margin between 57% and 59%

· Adjusted EBITDA between (1%) and 4% growth

Webcast and Conference Call Details

In conjunction with this announcement, Harvard Bioscience will

be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will

be posted to the Company’s Investor Relations website shortly before the webcast begins.

Analysts who would like to join the call and ask

a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only

webcast should go to our events and presentations on the investor website here.

Use of Non-GAAP Financial Information

In this press release we have included non-GAAP financial information,

including one or more of adjusted operating income (loss), adjusted operating margin, adjusted gross margin, adjusted net income (loss),

adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, net debt, adjusted gross profit, and non-GAAP revenue

on a constant currency basis. We believe that this non-GAAP financial information provides investors with an enhanced understanding of

the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses

and income resulting from items that we do not believe are reflective of the underlying operations of the business. Items excluded include

stock-based compensation, amortization of intangibles related to acquisitions, Non-GAAP restructuring related charges, other operating

expenses, goodwill impairment, interest and other expense, net, income taxes, and the tax impact of reconciling items. Management believes

that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors

and financial analysts in assessing the Company’s operating performance.

Historical non-GAAP financial information included herein is accompanied

by a reconciliation to the nearest corresponding GAAP measure, which is included below. In addition, the forward-looking Adjusted gross

margin and Adjusted EBITDA guidance for the fourth quarter of 2026 and full-year 2026 excludes potential charges or gains that may be

recorded during the fiscal year, including among other things, restructuring and reorganization expenses, and non-GAAP restructuring related

expenses. The Company has not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable

GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains

is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such

reconciliations would imply a degree of precision and certainty that could be misleading to investors. Such items could have a substantial

impact on GAAP measures of the Company’s financial performance.

The non-GAAP financial information provided in this press release

should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP

and may be different from other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and

seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug

and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned

academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations.

With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers

around the world.

For more information, please visit our website

at www.harvardbioscience.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of

the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified

by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,”

“estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical

matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational

performance including revenues, adjusted gross margin, adjusted EBITDA, gross margin, cash and debt position, balance sheet, growth, adoption

and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic

conditions. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions,

and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s

actual results to differ materially from those described in its forward-looking statements include those described in the “Risk

Factors” section of the Company’s most recently filed Annual Report on Form 10-K, as well as in the Company’s other

filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions

as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to

reflect any change in expectations, even as new information becomes available.

Investor Inquiries:

Mark Frost

Chief Financial Officer

(508) 893-3120

investors@harvardbioscience.com

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Statements Of Operations

(Unaudited, in thousands, except

per share data)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Revenues

$ 22,196

$ 20,591

$ 65,678

$ 62,815

Cost of revenues

9,889

8,570

28,497

27,077

Gross profit

12,307

12,021

37,181

35,738

Sales and marketing expenses

5,420

4,613

16,155

14,123

General and administrative expenses

4,756

4,176

14,075

13,623

Research and development expenses

2,258

2,132

7,037

6,642

Amortization of intangible assets

365

855

2,005

3,177

Goodwill impairment

-

-

-

47,951

Other operating expenses

658

48

1,211

512

Total operating expenses

13,457

11,824

40,483

86,028

Operating (loss) income

(1,150 )

197

(3,302 )

(50,290 )

Other income (expense):

Interest expense

(1,783 )

(1,323 )

(5,304 )

(3,257 )

Other income (expense), net

238

(8 )

(292 )

(635 )

Total other expense

(1,545 )

(1,331 )

(5,596 )

(3,892 )

Loss before income taxes

(2,695 )

(1,134 )

(8,898 )

(54,182 )

Income tax (benefit) expense

(72 )

97

59

(329 )

Net loss

$ (2,623 )

$ (1,231 )

$ (8,957 )

$ (53,853 )

Loss per share:

Basic and diluted loss per share *

$ (0.58 )

$ (0.28 )

$ (1.99 )

$ (12.15 )

Weighted-average common shares:

Basic and diluted *

4,561

4,456

4,500

4,432

* Retroactively presented to reflect 1-for-10 reverse

stock split effective on March 13, 2026.

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

September 30, 2026

December 31, 2025

Assets

Cash and cash equivalents

$ 4,856

$ 8,614

Accounts receivable, net

14,912

16,043

Inventories

23,491

20,805

Other current assets

2,718

2,763

Total current assets

45,977

48,225

Property, plant and equipment

5,399

4,787

Goodwill and other intangibles

15,481

17,198

Other long-term assets

8,442

9,861

Total assets

$ 75,299

$ 80,071

Liabilities and Stockholders' Equity

Other current liabilities

26,127

21,960

Total current liabilities

26,127

21,960

Long-term debt, net

37,153

35,870

Other long-term liabilities

6,914

8,507

Stockholders’ equity

5,105

13,734

Total liabilities and stockholders’ equity

$ 75,299

$ 80,071

HARVARD BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

Nine Months Ended

September 30, 2026

September 30, 2025

Cash flows from operating activities:

Net loss

$ (8,957 )

$ (53,853 )

Adjustments to operating cash flows

6,083

54,087

Changes in operating assets and liabilities

2,289

6,591

Net cash (used in) provided by operating activities

(585 )

6,825

Cash flows from investing activities:

Additions to property, plant and equipment

(2,041 )

(809 )

Acquisition of intangible assets

(838 )

(455 )

Net cash used in investing activities

(2,879 )

(1,264 )

Cash flows from financing activities:

Repayment of term debt

-

(3,000 )

Payment of debt issuance costs

(131 )

(687 )

Proceeds from exercise of warrants and stock purchase plan

150

46

Taxes paid related to net share settlement of equity awards

(111 )

(99 )

Net cash used in financing activities

(92 )

(3,740 )

Effect of exchange rate changes on cash and cash equivalents

(202 )

888

(Decrease) increase in cash and cash equivalents

(3,758 )

2,709

Cash and cash equivalents at the beginning of period

8,614

4,108

Cash and cash equivalents at the end of period

$ 4,856

$ 6,817

HARVARD BIOSCIENCE, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(in thousands, except per share

data and percentages)

Three Months Ended

Nine Months Ended

September 30, 2026

September 30, 2025

September 30, 2026

September 30, 2025

GAAP operating (loss) income

$ (1,150 )

$ 197

$ (3,302 )

$ (50,290 )

Stock-based compensation

436

324

1,073

1,396

Acquired asset amortization

365

855

2,005

3,177

Goodwill impairment

-

-

-

47,951

Other operating expenses (1)

658

48

1,211

512

Other adjustments (2)

864

93

1,535

135

Adjusted operating income

$ 1,173

$ 1,517

$ 2,522

$ 2,881

Operating margin

(5.2 )%

1.0 %

(5.0 )%

(80.1 )%

Adjusted operating margin

5.3 %

7.4 %

3.8 %

4.6 %

GAAP net loss

$ (2,623 )

$ (1,231 )

$ (8,957 )

$ (53,853 )

Stock-based compensation

436

324

1,073

1,396

Acquired asset amortization

365

855

2,005

3,177

Goodwill impairment

-

-

-

47,951

Other operating expenses (1)

658

48

1,211

512

Other adjustments (2)

864

93

1,535

135

Income taxes

12

(250 )

727

(266 )

Adjusted net loss

(288 )

(161 )

(2,406 )

(948 )

Depreciation & amortization

588

468

1,669

1,417

Interest and Other income (expense), net (3)

1,545

1,331

5,596

3,892

Adjusted income taxes (4)

(84 )

347

(668 )

(63 )

Adjusted EBITDA

$ 1,761

$ 1,985

$ 4,191

$ 4,298

Adjusted EBITDA margin

7.9 %

9.6 %

6.4 %

6.8 %

Diluted loss per share (GAAP)

$ (0.58 )

$ (0.28 )

$ (1.99 )

$ (12.15 )

Diluted adjusted loss per share

$ (0.06 )

$ (0.04 )

$ (0.53 )

$ (0.21 )

Weighted-average common shares:

Diluted GAAP *

4,561

4,456

4,500

4,432

Diluted Adjusted *

4,561

4,456

4,500

4,432

September 30,

2026

2025

Debt, including unamortized deferred financing costs

$ 37,153

$ 33,967

Unamortized deferred financing costs

2,847

383

Cash and cash equivalents

(4,856 )

(6,817 )

Net debt

$ 35,144

$ 27,533

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

(1) Other operating expenses for the three months ended September 30, 2026 includes $658 thousand of restructuring-related charges compared to $48 thousand of restructuring-related charges for the three months ended September 30, 2025. Other operating expenses for the nine months ended September 30, 2026 includes $1.2 million of restructuring-related charges compared to $171 thousand of restructuring-related charges and $341 thousand related to ERTC Fees for the nine months ended September 30, 2025.

(2) Other adjustments for the three months ended September 30, 2026 includes

$864 thousand of Non-GAAP restructuring-related charges compared to $93 thousand of Non-GAAP restructuring-related charges for the three

months ended September 30, 2025. Other adjustments expenses for the nine months ended September 30, 2026 includes $1.5 million of Non-GAAP

restructuring-related charges compared to $135 thousand of Non-GAAP restructuring-related charges for the nine months ended September

30, 2025.

(3) Interest expense for the three months ended September 30, 2026 was $1.8 million compared to $1.3 million for the three months

ended September 30, 2025. Interest expense for the nine months ended September 30, 2026 was $5.3 million compared to $3.3 million for

the nine months ended September 30, 2025.

(4) Adjusted income taxes includes the tax effect of adjusting

for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

HARVARD BIOSCIENCE, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(in thousands, except per share data and percentages)

Three Months Ended September 30,

Nine Months Ended September 30,

Non-GAAP revenue on a constant currency basis

2026

2025

Growth Rates

2026

2025

Growth Rates

Total revenues

$ 22,196

$ 20,591

7.8 %

65,678

62,815

4.6 %

Effects of foreign currency rate fluctuations

7

-

(723 )

Revenue on a constant currency basis

$ 22,203

$ 20,591

7.8 %

64,955

62,815

3.4 %

Three Months Ended September 30,

Nine Months Ended September 30,

Non-GAAP Gross Profit and Non-GAAP Gross Margin

2026

2025

2026

2025

Amount

Margin

Amount

Margin

Amount

Margin

Amount

Margin

(in thousands)

Gross profit

$ 12,307

55.4 %

$ 12,021

58.4 %

$ 37,181

56.6 %

$ 35,738

56.9 %

Adjustments:

Stock-based compensation expense - cost of sales

13

0.1 %

18

0.1 %

34

0.1 %

79

0.1 %

Depreciation and amortization - cost of sales

201

0.9 %

156

0.8 %

598

0.9 %

440

0.7 %

Other adjustments - cost of sales (1)

143

0.6 %

-

0.0 %

188

0.3 %

-

0.0 %

Non-GAAP gross profit

$ 12,664

57.1 %

$ 12,195

59.2 %

$ 38,001

57.9 %

$ 36,257

57.7 %

(1) Other adjustments - cost of sales for the three months ended September 30, 2026 includes $143 thousand of Non-GAAP restructuring-related charges. Other adjustments - cost of sales for the nine months ended September  30, 2026 includes $188 thousand of Non-GAAP restructuring-related charges.

GRAPHIC

GRAPHIC

Filename: logo.jpg · Sequence: 6

Binary file (7010 bytes)

Download logo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Nov. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 10, 2026

Entity File Number

001-33957

Entity Registrant Name

HARVARD BIOSCIENCE, INC.

Entity Central Index Key

0001123494

Entity Tax Identification Number

04-3306140

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

84 October Hill Road

Entity Address, City or Town

Holliston

Entity Address, State or Province

MA

Entity Address, Postal Zip Code

01746

City Area Code

(508)

Local Phone Number

893-8999

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

HBIO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration